 |
 |
|
|
|  PubMed
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
4 January 2005 | Volume 142 Issue 1 | Pages 37-46
Background: Experimental models and observational studies suggest that vitamin E supplementation may prevent cardiovascular disease and cancer. However, several trials of high-dosage vitamin E supplementation showed non–statistically significant increases in total mortality.
Purpose: To perform a meta-analysis of the dose–response relationship between vitamin E supplementation and total mortality by using data from randomized, controlled trials.
Patients: 135 967 participants in 19 clinical trials. Of these trials, 9 tested vitamin E alone and 10 tested vitamin E combined with other vitamins or minerals. The dosages of vitamin E ranged from 16.5 to 2000 IU/d (median, 400 IU/d).
Data Sources: PubMed search from 1966 through August 2004, complemented by a search of the Cochrane Clinical Trials Database and review of citations of published reviews and meta-analyses. No language restrictions were applied.
Data Extraction: 3 investigators independently abstracted study reports. The investigators of the original publications were contacted if required information was not available.
Data Synthesis: 9 of 11 trials testing high-dosage vitamin E (
Limitations: High-dosage (
Conclusion: High-dosage (
Contribution
Cautions
Implications
–The Editors
On the basis of the premise that vitamin E reduces oxidative stress, many clinical trials have tested vitamin E supplementation as a therapy to prevent various chronic diseases. The results of these trials have been largely disappointing (1-3). Three recent meta-analyses, which did not consider dose–response relationships, reported no overall effect of vitamin E on survival (4-6). However, several trials of high-dosage vitamin E supplementation have reported non–statistically significant increases in total mortality. Because individual trials typically tested only 1 dosage of vitamin E and large-scale trials with several dosages are not feasible, we performed this dose–response meta-analysis to evaluate a potential dose-dependent effect of vitamin E supplementation. We focused on all-cause mortality because this end point has unambiguous clinical relevance and, in contrast to cause-specific events such as cardiovascular morbidity or death, is resistant to miscoding.
We searched for all reports of clinical trials (with no language restrictions) that tested the effect of vitamin E supplementation in humans. We performed a MEDLINE search by using the Medical Subject Heading (MeSH) terms vitamin E, antioxidant vitamins, alpha tocopherol, tocopherol, and clinical trials. The search period was 1966 through August 2004. We complemented the MEDLINE search by searching the Cochrane database of randomized, controlled trials; reviewing the reference lists from original research, review articles, and previous meta-analyses; and reviewing the files of the investigators.
Our prespecified inclusion criteria were 1) random allocation of participants, 2) use of vitamin E supplementation alone or combined with other vitamins or minerals, 3) presence of a control or placebo group, 4) study sample limited to men or nonpregnant women, 5) duration of vitamin E supplementation and follow-up longer than 1 year, and 6) occurrence of at least 10 deaths in the trial. The restriction to include studies with follow-up longer than 1 year and at least 10 deaths was determined a priori because we anticipated that many small trials did not collect mortality data. We contacted the investigators of the original studies if information required to establish inclusion criteria or information on trial design or mortality results was not available in the published reports. Three investigators independently abstracted the articles. They resolved disagreements by consensus. We converted the dosage of vitamin E in each trial to international units per day (IU/d) (7). Only 1 trial (8) used 2 vitamin E dosage groups (400 and 800 IU/d); however, all-cause mortality data were available for both vitamin E groups combined (9), not for the separate dosages. For this trial, we assigned all deaths in the 2 vitamin E groups to the average dosage of 600 IU/d.
Statistical Analysis
We conducted all analyses according to the intention-to-treat principle. For trials with a factorial design, we based main results on 2-way analyses, that is, all trial participants receiving vitamin E were compared with all participants not receiving it. We used a 2-level hierarchical logistic regression model (10, 11) to evaluate the association between vitamin E supplementation and all-cause mortality. In the first within-study level, we specified a logistic model for the probability of death as a function of randomized assignment to vitamin E treatment in each trial. In the second between-study level, we first introduced an indicator variable for high-dosage vitamin E trials (
We performed several sensitivity analyses to evaluate the robustness of the results. First, we replicated the analyses assuming different knot values (100, 200, 300, 400, or 500 IU of vitamin E per day) for the quadratic-linear, dose–response model. The results were virtually insensitive to the selected knot for the quadratic-linear model, and the shape of the dose–response curve remained essentially unchanged (not shown). Then, we repeated the analyses on the basis of 4-way analysis of factorial trials. In this analysis, we restricted data from factorial trials to participants who were not exposed to the second factorial intervention. In addition, we included other study-specific explanatory variables as second-level covariates in the categorical and dose–response hierarchical models. Because of the limited number of trials, we separately evaluated the effect of adding the following variables: sex distribution, mean age, use of other vitamins or minerals combined with vitamin E, and average duration of follow-up. Finally, we evaluated the influence of each trial on the results by removing each individual study from the analysis.
In all analyses, we estimated and inferred vitamin E effects by using population-average models with robust standard errors (11, 15). Population-average models estimate the effects at different vitamin E dosages averaged across all trials, whereas robust standard errors are relatively insensitive to model misspecification. We transformed the logistic model results into risk differences and risk ratios of the effect of vitamin E supplementation compared with control for easier clinical interpretability. We obtained CIs for risk differences and risk ratios by using the delta method. We performed analyses by using S-PLUS 2000 (Mathsoft, Inc., Seattle, Washington) (16) and HLM 5 (Scientific Software International, Lincolnwood, Illinois) (17).
Role of the Funding Sources
The funding sources had no role in the collection, analysis, and interpretation of the data or in the decision to submit the manuscript for publication.
Figure 1 summarizes the trial selection process. We identified 36 randomized, controlled trials with follow-up longer than 1 year. We excluded 12 trials with fewer than 10 deaths (18-29), 3 trials with unavailable mortality data (30-32), and 2 trials in which mortality data were not separated from a composite end point (33, 34). Nineteen trials (8, 35-53) met our inclusion criteria (Table 1). The selected trials were reported between 1993 and 2004, and their sample sizes varied between 196 and 29 584 participants. The total number of participants was 135 967, with 12 504 all-cause deaths. The reported mean age ranged from 47 to 84 years. Seventeen trials included men and women, 1 trial included only men, and 1 trial included only women. Most trials targeted populations at high risk for a chronic disease, most often coronary heart disease. Nine of 19 trials used vitamin E alone, while the other 10 trials combined vitamin E with other vitamins or minerals. All but 3 trials (42, 43, 51) were placebo-controlled and double-blind. Average follow-up ranged from 1.4 to 8.2 years. Vitamin E dosage varied between 16.5 and 2000 IU/d, with a median dosage of 400 IU/d. High-dosage (REVIEW
Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality
400 IU/d) showed increased risk (risk difference > 0) for all-cause mortality in comparisons of vitamin E versus control. The pooled all-cause mortality risk difference in high-dosage vitamin E trials was 39 per 10 000 persons (95% CI, 3 to 74 per 10 000 persons; P = 0.035). For low-dosage vitamin E trials, the risk difference was –16 per 10 000 persons (CI, –41 to 10 per 10 000 persons; P > 0.2). A dose–response analysis showed a statistically significant relationship between vitamin E dosage and all-cause mortality, with increased risk of dosages greater than 150 IU/d. 400 IU/d) trials were often small and were performed in patients with chronic diseases. The generalizability of the findings to healthy adults is uncertain. Precise estimation of the threshold at which risk increases is difficult. 400 IU/d) vitamin E supplements may increase all-cause mortality and should be avoided.
Editors' Notes
Top
Editors' Notes
Methods
Results
Discussion
Author & Article Info
References
Context
400 IU/d for at least 1 year) increased all-cause mortality. Benefits or harms of lower-dosage supplementation were unclear.
Methods
Top
Editors' Notes
Methods
Results
Discussion
Author & Article Info
References
Search Strategy and Inclusion Criteria400 IU/d) to evaluate the differences in effect of high- and low-dosage vitamin E supplementation. For dose–response analyses, we replaced the above indicator variable with a quadratic-linear spline model (12) for log-dose of vitamin E. The quadratic-linear spline assumed a quadratic trend below the median vitamin E dosage across studies (400 IU/d) and a linear trend more than this dosage. We selected the lower quadratic term to allow for nonlinear responses, while ensuring a null effect for 0 dose level. We restricted the upper term to be linear to avoid implausible shapes at high dosages of vitamin E. Thus, this quadratic-linear spline model is more flexible, less influenced by extreme values, and more plausible than the usual linear or quadratic polynomial models (12-14).
Results
Top
Editors' Notes
Methods
Results
Discussion
Author & Article Info
References
Study Description400 IU/d) trials, however, were smaller on average, and only 40thinsp;950 patients (30.1% of all randomly assigned patients) participated in high-dosage trials.
|
|
Combined Effect of Vitamin E on All-Cause Mortality
The average death risk across trials in the control groups was 1022 per 10 000 persons. Overall, vitamin E supplementation did not affect all-cause mortality. The pooled risk difference comparing vitamin E with control was 10 per 10 000 persons (95% CI, –18 to 38 per 10 000 persons) and the risk ratio was 1.01 (CI, 0.98 to 1.04; P > 0.2) (Figure 2). However, there was significant heterogeneity of study results (P = 0.020) that was explained by differences in results between low-dosage (<400 IU/d) and high-dosage (400 IU/d) vitamin E trials (P = 0.18 for residual heterogeneity). In 8 trials testing low-dosage vitamin E supplementation, the pooled risk difference comparing vitamin E with control was –16 per 10 000 persons (CI, –41 to 10 per 10 000 persons) and the risk ratio was 0.98 (CI, 0.96 to 1.01; P > 0.2). In 11 trials testing high-dosage vitamin E, the pooled risk difference was 39 per 10 000 persons (CI, 3 to 74 per 10 000 persons) and the risk ratio was 1.04 (CI, 1.01 to 1.07; P = 0.035) (Figure 2).
|
In dose–response analysis, all-cause mortality progressively increased as vitamin E dosage increased by more than 150 IU/d, and the pointwise 95% CIs for the risk difference did not include 0 for dosages greater than 900 IU/d (Figure 3). Table 2 displays risk differences estimated from the model at different vitamin E dosage levels. For dosages less than 150 IU/d, all-cause mortality slightly but nonsignificantly decreased. Both the linear and the quadratic components of the dose–response model were statistically significant (P = 0.027 and 0.037, respectively), indicating that this quadratic-linear model had increased explanatory ability compared with a simple linear model. In the dose–response analyses, no residual heterogeneity in vitamin E effects was observed after consideration of the different dosages (P = 0.15).
|
|
Sensitivity Analyses
In 4-way analysis, the overall pooled risk difference between vitamin E and control was 8 per 10 000 persons (CI, –23 to 39 per 10 000 persons; P > 0.2). As in 2-way analyses, there was significant heterogeneity (P = 0.039) that was explained after disaggregation of low- and high-dosage vitamin E trials (P > 0.2 for residual heterogeneity). The pooled risk difference for low-dosage vitamin E trials was –33 per 10 000 persons (CI, –60 to –5 per 10 000 persons; P = 0.021), and the pooled risk difference for high-dosage vitamin E trials was 34 per 10 000 persons (CI, 5 to 63 per 10 000 persons; P = 0.022) (Figure 4). The dose–response relationship for 4-way analyses was very similar to that for 2-way analyses (data not shown), with significant linear and quadratic components (P = 0.027 and 0.030, respectively) and no residual heterogeneity (P > 0.2).
|
The effect of vitamin E supplementation did not change appreciably after adjustment for differences in sex distribution, mean age, or average follow-up across trials (Table 3). However, when we controlled for the concomitant use of other vitamins or minerals, the reduction in all-cause mortality for low-dosage vitamin E trials was slightly attenuated (pooled risk difference, –6 per 10 000 persons [CI, –38 to 26 per 10 000 persons]) and the increase in risk of high-dosage vitamin E trials was more marked (pooled risk difference, 63 per 10 000 persons [CI, 6 to 119 per 10 000 persons]). Similar increases in all-cause mortality at high vitamin E dosages were observed in dose–response analyses after adjustment for use of other vitamins or minerals (Table 2).
|
The influence of each trial was approximately proportional to the number of deaths, and none seemed to be driving the results. The increased risk at high vitamin E dosages remained statistically significant after exclusion of each of the 11 high-dosage trials, with pooled all-cause mortality risk differences ranging from 28 to 55 per 10 000 persons.
Discussion
|
|---|
|
TopEditors' NotesMethodsResultsDiscussionAuthor & Article InfoReferences |
|---|
-tocopherol per day (corresponding to 1100 IU of synthetic vitamin E per day or 1500 IU of natural vitamin E per day) (1). The increase in all-cause mortality has obvious public health importance and represents a qualitative departure from previous findings. Three previous meta-analyses (4-6) that did not consider the dose-dependent effect of vitamin E concluded that vitamin E was neither beneficial nor harmful. A recent meta-analysis that examined the effects of antioxidants, not specifically vitamin E, in preventing cancer noted a possible increase in all-cause mortality (54). However, in an accompanying comment, Forman and Altman (55) cautioned that these mortality analyses were exploratory and incomplete. A strength of our paper is the systematic search for trials that presented mortality data.
Although vitamin E is considered relatively safe compared to other fat-soluble vitamins (56), an increase in mortality at high dosages of vitamin E is biologically plausible. In fact, some researchers warned against the long-term administration of mega-dosages of vitamin E because it could be associated with many adverse effects (57). In vitro studies have shown that vitamin E may have pro-oxidant effects at high doses (58, 59). In in vitro models, the pro-oxidant effect of vitamin E on low-density lipoproteins is related to the production of the -tocopheroxyl radical, which can be inhibited by co-antioxidants such as vitamin C (60). However, the trials that combined high-dosage vitamin E with vitamin C (48, 49, 51) showed increased mortality in the vitamin E groups, with the exception of the small Polyp Prevention Study (PPS) (46). High dosages of vitamin E may displace other fat-soluble antioxidants (for example, 
-tocopherol) (61), disrupting the natural balance of antioxidant systems and increasing vulnerability to oxidative damage. Vitamin E may also inhibit human cytosolic glutathione S-transferases, which help detoxify drugs and endogenous toxins (62).
Vitamin E also has anticoagulant properties, possibly by interfering with vitamin K–dependent clotting mechanisms (63). In fact, the Alpha-Tocopherol, Beta Carotene (ATBC) Cancer Prevention Study (38) showed a statistically significant increased risk for hemorrhagic stroke among participants assigned to vitamin E. The early literature also suggested that vitamin E might affect the conversion of ß-carotene to vitamin A and the tissue distribution of vitamin A in animal studies, but the relevance of this mechanism in humans has never been established (57, 64). Several of the high-dosage studies in our meta-analysis that showed increased mortality were performed in Europe (8, 48, 49), where over-the-counter use of high-dosage supplements of ß-carotene or vitamin A is uncommon. It is thus unlikely that vitamin E's adverse effects are mediated through ß-carotene or vitamin A.
Irregular use of high-dosage vitamin E may lead to withdrawal effects. Indeed, after reports that anginal symptoms returned after tapering of large dosages of vitamin E, Anderson and Reid (65) recruited 15 patients with stable angina for a placebo-controlled discontinuation trial. These patients had been taking 400 to 2400 IU of vitamin E per day for long periods. Eight of these patients were randomly assigned to a dosage of vitamin E that was equal to or greater than what they were taking; symptoms in these patients did not change for the duration of the trial (9 weeks). In 4 of the 7 patients randomly assigned to placebo, anginal symptoms worsened (P = 0.03); 3 of these patients had to discontinue the trial prematurely. This small study has not been replicated, and the effects of discontinuing high dosages of vitamin E are unknown.
Another concern is that concomitant use of other vitamins or minerals, particularly ß-carotene, as part of the study intervention may explain the observed increase in mortality associated with vitamin E. However, only 3 of the 11 high-dosage vitamin E studies tested a combination of vitamin E with ß-carotene. Furthermore, adjustment for combined use of vitamin E with other vitamins or minerals did not modify our findings.
Our analysis may have other limitations. The small size of several of the trials plus inconsistent reporting of events across trials precluded a detailed dose–response analysis of cause-specific end points. However, in the 2 largest high-dosage vitamin E trials reporting cause-specific deaths (Cambridge Heart Antioxidant Study [CHAOS] [8] and Medical Research Council/British Heart Foundation Heart Protection Study [MRC/BHF HPS] [49]), the relative risk for cardiovascular mortality associated with vitamin E exceeded 1.0. The biological activity of vitamin E compounds also differs among isomer forms (1). Hence, biological activities of vitamin E compounds are reported relative to all-rac--tocopherol acetate on the basis of in vivo assays (1). We converted the vitamin E dosages of the studies included in our meta-analysis to IU/d relative to all-rac--tocopherol acetate (7) for standardization across studies. Publication bias is also a potential source of bias in meta-analysis. We would expect, however, underreporting of vitamin E studies that failed to show a beneficial effect, which would bias against our findings. In addition, high-dosage vitamin E trials were often performed in patients with various chronic diseases, and we could not evaluate the generalizability of our findings to healthy adult populations. Finally, the ideal study design to assess dose response is a long-term, large trial with several doses. Such trials are almost impossible to conduct, especially with total mortality as an outcome. Hence, although precisely identifying the threshold at which risk increases is difficult, our meta-analysis probably provides the best estimate of the dose–response effect of vitamin E supplementation on mortality.
The possibility of a small mortality benefit with low-dosage vitamin E supplementation also deserves comment. The mortality reduction in low-dosage trials was not statistically significant in the primary analysis, although in secondary analyses based on 4-way data, the pooled risk difference for low-dosage vitamin E trials was –33 per 10 000 persons (P = 0.021). The effect of vitamin E in low-dosage studies, however, must be interpreted with caution because these studies were often performed in malnourished populations or used other vitamins or minerals in combination with vitamin E. Further research is needed to determine whether low-dosage vitamin E supplementation is beneficial in western populations.
Vitamin E supplements are regularly consumed in the United States (66), particularly by patients with established cardiovascular diseases and cancer (67). Furthermore, vitamin E supplements are often taken at high dosages (for instance, 64% of vitamin E users in the Physicians' Health Study [68] took 400 IU/d), far exceeding intake derived from dietary sources (9.3 mg of -tocopherol equivalents on average per day [approximately 14 IU/d]) (1). On the basis of our study, high-dosage vitamin E supplementation is clearly unjustified. Policymaking bodies, which currently do not recommend antioxidant vitamin supplement use to the general population (1-3), should also caution the public against the use of high-dosage vitamin E supplementation. Current practice guidelines, however, recommend the use of vitamin E supplementation to delay the progression of Alzheimer disease (69, 70). This recommendation may be premature until larger randomized, controlled clinical trials evaluate the efficacy and safety of high-dosage vitamin E supplementation in patients with Alzheimer disease.
High-dosage vitamin supplementation is often assumed to be at worst innocuous. In view of the increased mortality associated with high dosages of ß-carotene (4) and now vitamin E, use of any high-dosage vitamin supplements should be discouraged until evidence of efficacy is documented from appropriately designed clinical trials.
Author and Article Information
|
|---|
|
TopEditors' NotesMethodsResultsDiscussionAuthor & Article InfoReferences |
|---|
Note: J.A. Baron provided unpublished mortality data from the Polyp Prevention Study.
Grant Support: Dr. Pastor-Barriuso was supported in part by a grant from the Instituto de Salud Carlos III (EPY 1261/02).
Potential Financial Conflicts of Interest:Grants received: R.A. Riemersma (Roche).
Requests for Single Reprints: Edgar R. Miller III, MD, PhD, Welch Center for Prevention, Epidemiology and Clinical Research, The Johns Hopkins Medical Institutions, 2024 East Monument Street, Suite 2-624, Baltimore, MD 21205-2223; e-mail, ermiller{at}jhmi.edu.
Current Author Addresses: Dr. Miller: Welch Center for Prevention, Epidemiology and Clinical Research, The Johns Hopkins Medical Institutions, 2024 East Monument Street, Suite 2-624, Baltimore, MD 21205-2223.
Dr. Pastor-Barriuso: Division of Biostatistics, National Center for Epidemiology, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Dr. Dalal: Division of Cardiology, Department of Medicine, The Johns Hopkins Medical Institutions, BRADY 604, Baltimore, MD 21205.
Dr. Riemersma: Cardiovascular Research Unit, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh EH8 9XF, Scotland, United Kingdom.
Dr. Appel: Welch Center for Prevention, Epidemiology and Clinical Research, The Johns Hopkins Medical Institutions, 2024 East Monument Street, Suite 2-618, Baltimore, MD 21205-2223.
Dr. Guallar: Welch Center for Prevention, Epidemiology and Clinical Research, Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, 2024 East Monument Street, Suite 2-639, Baltimore, MD 21205-2223.
Author Contributions: Conception and design: E.R. Miller, E. Guallar.
Analysis and interpretation of the data: E.R. Miller, R. Pastor-Barriuso, D. Dalal, R.A. Riemersma, L.J. Appel, E. Guallar.
Drafting of the article: E.R. Miller, R. Pastor-Barriuso, E. Guallar.
Critical revision of the article for important intellectual content: E.R. Miller, R. Pastor-Barriuso, D. Dalal, R.A. Riemersma, L.J. Appel, E. Guallar.
Final approval of the article: E.R. Miller, R. Pastor-Barriuso, D. Dalal, R.A. Riemersma, L.J. Appel, E. Guallar.
Statistical expertise: R. Pastor-Barriuso, E. Guallar.
Administrative, technical, or logistic support: D. Dalal, E. Guallar.
Collection and assembly of data: E.R. Miller, D. Dalal, R.A. Riemersma, E. Guallar.
References
|
|---|
|
TopEditors' NotesMethodsResultsDiscussionAuthor & Article InfoReferences |
|---|
1. Institute of Medicine. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. A report of the Panel on Dietary Antioxidants and Related Compounds, Subcommittees on Upper Reference Levels of Nutrients and Interpretation and Uses of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes Food Nutrition Board. Washington, DC: National Academies Pr; 2000.
2. Tribble DL. AHA Science Advisory. Antioxidant consumption and risk of coronary heart disease: emphasis on vitamin C, vitamin E, and beta-carotene: A statement for healthcare professionals from the American Heart Association. Circulation. 1999;99:591-5. [PMID: 9927409].
3. Morris CD, Carson S. Routine vitamin supplementation to prevent cardiovascular disease: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2003;139:56-70. [PMID: 12834320].
4. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet. 2003;361:2017-23. [PMID: 12814711].[Medline]
5. Shekelle PG, Morton SC, Jungvig LK, Udani J, Spar M, Tu W, et al. Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease. J Gen Intern Med. 2004;19:380-9. [PMID: 15061748].[Medline]
6. Eidelman RS, Hollar D, Hebert PR, Lamas GA, Hennekens CH. Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease. Arch Intern Med. 2004;164:1552-6. [PMID: 15277288].
7. Bieri JG, McKenna MC. Expressing dietary values for fat-soluble vitamins: changes in concepts and terminology. Am J Clin Nutr. 1981;34:289-95. [PMID: 6259921].
8. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781-6. [PMID: 8622332].[Medline]
9. Mitchinson MJ, Stephens NG, Parsons A, Bligh E, Schofield PM, Brown MJ. Mortality in the CHAOS trial [Letter]. Lancet. 1999;353:381-2. [PMID: 9950454].[Medline]
10. Wong GY, Mason WM. The hierarchical logistic-regression model for multilevel analysis. Journal of the American Statistical Association. 1985;80:513-24.
11. Raudenbush SW, Bryk AS. Hierarchical Linear Models: Applications and Data Analysis Methods. 2nd ed. Newbury Park, CA: Sage Publications; 2002.
12. Greenland S. Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology. 1995;6:356-65. [PMID: 7548341].[Medline]
13. Goetghebeur E, Pocock SJ. Detection and estimation of J-shaped risk-response relationships. Journal of the Royal Statistical Society. Series A. 1995;158:107-21.
14. Pastor R, Guallar E. Use of two-segmented logistic regression to estimate change-points in epidemiologic studies. Am J Epidemiol. 1998;148:631-42. [PMID: 9778169].
15. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44:1049-60. [PMID: 3233245].[Medline]
16. S-PLUS 2000 User's Guide. Seattle, WA: Mathsoft, Inc.; 1999.
17. Raudenbush SW, Bryk AS, Cheong YF, Congdon R. HLM 5: Hierarchical Linear and Nonlinear Modeling. 2nd ed. Lincolnwood, IL: Scientific Software International; 2001.
18. McKeown-Eyssen G, Holloway C, Jazmaji V, Bright-See E, Dion P, Bruce WR. A randomized trial of vitamins C and E in the prevention of recurrence of colorectal polyps. Cancer Res. 1988;48:4701-5. [PMID: 3293777].
19. Berson EL, Rosner B, Sandberg MA, Hayes KC, Nicholson BW, Weigel-DiFranco C, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol. 1993;111:761-72. [PMID: 8512476].
20. Roncucci L, Di Donato P, Carati L, Ferrari A, Perini M, Bertoni G, et al. Antioxidant vitamins or lactulose for the prevention of the recurrence of colorectal adenomas. Colorectal Cancer Study Group of the University of Modena and the Health Care District 16. Dis Colon Rectum. 1993;36:227-34. [PMID: 8449125].
21. Orndahl G, Grimby G, Grimby A, Johansson G, Wilhelmsen L. Functional deterioration and selenium-vitamin E treatment in myotonic dystrophy. A placebo-controlled study. J Intern Med. 1994;235:205-10. [PMID: 8120515].[Medline]
22. Takamatsu S, Takamatsu M, Satoh K, Imaizumi T, Yoshida H, Hiramoto M, et al. Effects on health of dietary supplementation with 100 mg D-alpha-tocopheryl acetate, daily for 6 years. J Int Med Res. 1995;23:342-57. [PMID: 8529777].[Medline]
23. Richer S. Multicenter ophthalmic and nutritional age-related macular degeneration study—part 2: antioxidant intervention and conclusions. J Am Optom Assoc. 1996;67:30-49. [PMID: 8825017].[Medline]
24. Hofstad B, Almendingen K, Vatn M, Andersen SN, Owen RW, Larsen S, et al. Growth and recurrence of colorectal polyps: a double-blind 3-year intervention with calcium and antioxidants. Digestion. 1998;59:148-56. [PMID: 9586828].[Medline]
25. de Waart FG, Kok FJ, Smilde TJ, Hijmans A, Wollersheim H, Stalenhoef AF. Effect of glutathione S-transferase M1 genotype on progression of atherosclerosis in lifelong male smokers. Atherosclerosis. 2001;158:227-31. [PMID: 11500195].[Medline]
26. Wluka AE, Stuckey S, Brand C, Cicuttini FM. Supplementary vitamin E does not affect the loss of cartilage volume in knee osteoarthritis: a 2 year double blind randomized placebo controlled study. J Rheumatol. 2002;29:2585-91. [PMID: 12465157].
27. Graat JM, Schouten EG, Kok FJ. Effect of daily vitamin E and multivitamin-mineral supplementation on acute respiratory tract infections in elderly persons: a randomized controlled trial. JAMA. 2002;288:715-21. [PMID: 12169075].
28. Pasantes-Morales H, Quiroz H, Quesada O. Treatment with taurine, diltiazem, and vitamin E retards the progressive visual field reduction in retinitis pigmentosa: a 3-year follow-up study. Metab Brain Dis. 2002;17:183-97. [PMID: 12322788].[Medline]
29. Olmedilla B, Granado F, Blanco I, Vaquero M. Lutein, but not alpha-tocopherol, supplementation improves visual function in patients with age-related cataracts: a 2-y double-blind, placebo-controlled pilot study. Nutrition. 2003;19:21-4. [PMID: 12507634].[Medline]
30. DeCosse JJ, Miller HH, Lesser ML. Effect of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous polyposis. J Natl Cancer Inst. 1989;81:1290-7. [PMID: 2549261].
31. Zaridze D, Evstifeeva T, Boyle P. Chemoprevention of oral leukoplakia and chronic esophagitis in an area of high incidence of oral and esophageal cancer. Ann Epidemiol. 1993;3:225-34. [PMID: 8275193].[Medline]
32. Adler LA, Rotrosen J, Edson R, Lavori P, Lohr J, Hitzemann R, et al. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry. 1999;56:836-41. [PMID: 12892048].
33. Steiner M, Glantz M, Lekos A. Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. Am J Clin Nutr. 1995;62:1381S-1384S. [PMID: 7495235].
34. Desnuelle C, Dib M, Garrel C, Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2:9-18. [PMID: 11465936].[Medline]
35. Girodon F, Galan P, Monget AL, Boutron-Ruault MC, Brunet-Lecomte P, Preziosi P, et al. Impact of trace elements and vitamin supplementation on immunity and infections in institutionalized elderly patients: a randomized controlled trial. MIN. VIT. AOX. geriatric network. Arch Intern Med. 1999;159:748-54. [PMID: 10218756].
36. Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst. 1993;85:1483-92. [PMID: 8360931].
37. Zureik M, Galan P, Bertrais S, Mennen L, Czernichow S, Blacher J, et al. Effects of long-term daily low-dose supplementation with antioxidant vitamins and minerals on structure and function of large arteries. Arterioscler Thromb Vasc Biol. 2004;24:1485-91. [PMID: 15217803].
38. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med. 1994;330:1029-35. [PMID: 8127329].
39. Virtamo J, Pietinen P, Huttunen JK, Korhonen P, Malila N, Virtanen MJ, et al. Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA. 2003;290:476-85. [PMID: 12876090].
40. Li JY, Taylor PR, Li B, Dawsey S, Wang GQ, Ershow AG, et al. Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J Natl Cancer Inst. 1993;85:1492-8. [PMID: 8360932].
41. You WC, Chang YS, Heinrich J, Ma JL, Liu WD, Zhang L, et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. Eur J Cancer Prev. 2001;10:257-63. [PMID: 11432713].[Medline]
42. Dietary supplementation with N-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354:447-55. [PMID: 10465168].[Medline]
43. de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001;357:89-95. [PMID: 11197445].[Medline]
44. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:154-60. [PMID: 10639540].
45. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. Arch Ophthalmol. 2001;119:1439-52. [PMID: 11594943].
46. Greenberg ER, Baron JA, Tosteson TD, Freeman DH Jr, Beck GJ, Bond JH, et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. N Engl J Med. 1994;331:141-7. [PMID: 8008027].
47. McNeil JJ, Robman L, Tikellis G, Sinclair MI, McCarty CA, Taylor HR. Vitamin E supplementation and cataract: randomized controlled trial. Ophthalmology. 2004;111:75-84. [PMID: 14711717].[Medline]
48. Chylack LT Jr, Brown NP, Bron A, Hurst M, Köpcke W, Thien U, et al. The Roche European American Cataract Trial (REACT): a randomized clinical trial to investigate the efficacy of an oral antioxidant micronutrient mixture to slow progression of age-related cataract. Ophthalmic Epidemiol. 2002;9:49-80. [PMID: 11815895].[Medline]
49. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:23-33. [PMID: 12114037].[Medline]
50. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000;356:1213-8. [PMID: 11072938].[Medline]
51. Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002;288:2432-40. [PMID: 12435256].
52. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997;336:1216-22. [PMID: 9110909].
53. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group. Ann Neurol. 1998;43:318-25. [PMID: 9506548].[Medline]
54. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet. 2004;364:1219-28. [PMID: 15464182].[Medline]
55. Forman D, Altman D. Vitamins to prevent cancer: supplementary problems. Lancet. 2004;364:1193-4. [PMID: 15464163].[Medline]
56. Bendich A, Machlin LJ. Safety of oral intake of vitamin E. Am J Clin Nutr. 1988;48:612-9. [PMID: 3046299].
57. Roberts HJ. Perspective on vitamin E as therapy. JAMA. 1981;246:129-31. [PMID: 7241744].
58. Bowry VW, Stocker R. Tocopherol-mediated peroxidation. The prooxidant effect of vitamin E on the radical-initiated oxidation of human low-density lipoprotein. Journal of the American Chemical Society. 1993;115:6029-44.
59. Abudu N, Miller JJ, Attaelmannan M, Levinson SS. Vitamins in human arteriosclerosis with emphasis on vitamin C and vitamin E. Clin Chim Acta. 2004;339:11-25. [PMID: 14687889].[Medline]
60. Bowry VW, Mohr D, Cleary J, Stocker R. Prevention of tocopherol-mediated peroxidation in ubiquinol-10-free human low density lipoprotein. J Biol Chem. 1995;270:5756-63. [PMID: 7890704].
61. Huang HY, Appel LJ. Supplementation of diets with alpha-tocopherol reduces serum concentrations of gamma- and delta-tocopherol in humans. J Nutr. 2003;133:3137-40. [PMID: 14519797].
62. van Haaften RI, Haenen GR, van Bladeren PJ, Bogaards JJ, Evelo CT, Bast A. Inhibition of various glutathione S-transferase isoenzymes by RRR-alpha-tocopherol. Toxicol In Vitro. 2003;17:245-51. [PMID: 12781202].[Medline]
63. Dowd P, Zheng ZB. On the mechanism of the anticlotting action of vitamin E quinone. Proc Natl Acad Sci U S A. 1995;92:8171-5. [PMID: 7667263].
64. Bieri JG. Effect of excessive vitamins C and E on vitamin A status. Am J Clin Nutr. 1973;26:382-3. [PMID: 4694018].[Medline]
65. Anderson TW, Reid DB. A double-blind trial of vitamin E in angina pectoris. Am J Clin Nutr. 1974;27:1174-8. [PMID: 4214473].[Abstract]
66. Balluz LS, Kieszak SM, Philen RM, Mulinare J. Vitamin and mineral supplement use in the United States. Results from the third National Health and Nutrition Examination Survey. Arch Fam Med. 2000;9:258-62. [PMID: 10728113].
67. Satia-Abouta J, Kristal AR, Patterson RE, Littman AJ, Stratton KL, White E. Dietary supplement use and medical conditions: the VITAL study. Am J Prev Med. 2003;24:43-51. [PMID: 12554023].[Medline]
68. Muntwyler J, Hennekens CH, Manson JE, Buring JE, Gaziano JM. Vitamin supplement use in a low-risk population of US male physicians and subsequent cardiovascular mortality. Arch Intern Med. 2002;162:1472-6. [PMID: 12090883].
69. Rabins P, Blacker D, Bland W, Bright-Long L, Cohen E, Katz I, et al. Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias of Late Life. Arlington, VA: American Psychiatric Association; 1997. Accessed at http://www.psych.org/psych_pract/treatg/pg/pg_dementia_32701.cfm? on 1 October 2004.
70. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1154-66. [PMID: 11342679].
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  J.-Y. Cho, D. W. Kang, X. Ma, S.-H. Ahn, K. W. Krausz, H. Luecke, J. R. Idle, and F. J. Gonzalez Metabolomics reveals a novel vitamin E metabolite and attenuated vitamin E metabolism upon PXR activation J. Lipid Res., May 1, 2009; 50(5): 924 - 937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Thomson, M. P. Frenneaux, and J. C. Kaski Antioxidant treatment for heart failure: friend or foe? QJM, May 1, 2009; 102(5): 305 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R Jacobs Jr, M. D Gross, and L. C Tapsell Food synergy: an operational concept for understanding nutrition Am. J. Clinical Nutrition, May 1, 2009; 89(5): 1543S - 1548S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hemila and J. Kaprio Modification of the Effect of Vitamin E Supplementation on the Mortality of Male Smokers by Age and Dietary Vitamin C Am. J. Epidemiol., April 15, 2009; 169(8): 946 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Marian and G. Sacks Micronutrients and Older Adults Nutr Clin Pract, April 1, 2009; 24(2): 179 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Chung, E. M Balk, S. Ip, G. Raman, W. W Yu, T. A Trikalinos, A. H Lichtenstein, E. A Yetley, and J. Lau Reporting of systematic reviews of micronutrients and health: a critical appraisal Am. J. Clinical Nutrition, April 1, 2009; 89(4): 1099 - 1113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Nakhoul, R. Miller-Lotan, H. Awad, R. Asleh, K. Jad, N. Nakhoul, R. Asaf, N. Abu-Saleh, and A. P. Levy Pharmacogenomic effect of vitamin E on kidney structure and function in transgenic mice with the haptoglobin 2-2 genotype and diabetes mellitus Am J Physiol Renal Physiol, April 1, 2009; 296(4): F830 - F838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Lichtenstein Nutrient supplements and cardiovascular disease: a heartbreaking story J. Lipid Res., April 1, 2009; 50(Supplement): S429 - S433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Sedlak, M. Saleh, D. S. Higginson, B. D. Paul, K. R. Juluri, and S. H. Snyder Bilirubin and glutathione have complementary antioxidant and cytoprotective roles PNAS, March 31, 2009; 106(13): 5171 - 5176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Berry, J. K. Wathen, and M. Newell Bayesian model averaging in meta-analysis: vitamin E supplementation and mortality Clinical Trials, February 1, 2009; 6(1): 28 - 41. [Abstract] [PDF]
|
|
|
|
|
|
S. Greenland Weaknesses of Bayesian model averaging for meta-analysis in the study of vitamin E and mortality Clinical Trials, February 1, 2009; 6(1): 42 - 46. [PDF]
|
|
|
|
|
|
E. R Miller III and E. Guallar Vitamin E supplementation: what's the harm in that? Clinical Trials, February 1, 2009; 6(1): 47 - 49. [PDF]
|
|
|
|
 |
|
 S. M. Lippman, E. A. Klein, P. J. Goodman, M. S. Lucia, I. M. Thompson, L. G. Ford, H. L. Parnes, L. M. Minasian, J. M. Gaziano, J. A. Hartline, et al. Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) JAMA, January 7, 2009; 301(1): 39 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lin, N. R. Cook, C. Albert, E. Zaharris, J. M. Gaziano, M. Van Denburgh, J. E. Buring, and J. E. Manson Vitamins C and E and Beta Carotene Supplementation and Cancer Risk: A Randomized Controlled Trial J Natl Cancer Inst, January 7, 2009; 101(1): 14 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. McNear and S. A. Harrison Review: Current status of therapy in nonalcoholic fatty liver disease Therapeutic Advances in Gastroenterology, January 1, 2009; 2(1): 29 - 43. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Bashan, J. Kovsan, I. Kachko, H. Ovadia, and A. Rudich Positive and Negative Regulation of Insulin Signaling by Reactive Oxygen and Nitrogen Species Physiol Rev, January 1, 2009; 89(1): 27 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Ligibel, W. Demark-Wahnefried, and P. J. Goodwin Diet, Exercise, and Supplements: Guidelines for Cancer Survivors ASCO Educational Book, January 1, 2009; 2009(1): 541 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Collins, A. P. Tighe, S. A. Brunton, and P. M. Kris-Etherton Differences between Dietary Supplement and Prescription Drug Omega-3 Fatty Acid Formulations: A Legislative and Regulatory Perspective J. Am. Coll. Nutr., December 1, 2008; 27(6): 659 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. Goodman Assessing Toxicity in Cancer Chemoprevention Trials: The Other Side of the Coin Cancer Prevention Research, December 1, 2008; 1(7): 499 - 502. [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Lichtenstein, E. A. Yetley, and J. Lau Application of Systematic Review Methodology to the Field of Nutrition J. Nutr., December 1, 2008; 138(12): 2297 - 2306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Sesso, J. E. Buring, W. G. Christen, T. Kurth, C. Belanger, J. MacFadyen, V. Bubes, J. E. Manson, R. J. Glynn, and J. M. Gaziano Vitamins E and C in the Prevention of Cardiovascular Disease in Men: The Physicians' Health Study II Randomized Controlled Trial JAMA, November 12, 2008; 300(18): 2123 - 2133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Moher and A. C Tricco Issues related to the conduct of systematic reviews: a focus on the nutrition field Am. J. Clinical Nutrition, November 1, 2008; 88(5): 1191 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chitturi Review: Treatment options for nonalcoholic fatty liver disease Therapeutic Advances in Gastroenterology, November 1, 2008; 1(3): 173 - 189. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Hickey, C. Saunders, A. Partridge, N. Santoro, H. Joffe, and V. Stearns Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer Ann. Onc., October 1, 2008; 19(10): 1669 - 1680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Asleh, S. Blum, S. Kalet-Litman, J. Alshiek, R. Miller-Lotan, R. Asaf, W. Rock, M. Aviram, U. Milman, C. Shapira, et al. Correction of HDL Dysfunction in Individuals With Diabetes and the Haptoglobin 2-2 Genotype Diabetes, October 1, 2008; 57(10): 2794 - 2800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Dembe Can Moderate Doses of Vitamin E Protect against Lung Cancer? Am. J. Respir. Crit. Care Med., September 15, 2008; 178(6): 653 - 653. [Full Text] [PDF]
|
|
|
|
|
|
C. G. Slatore, D. H. Au, and E. White Can Moderate Doses of Vitamin E Protect against Lung Cancer? Am. J. Respir. Crit. Care Med., September 15, 2008; 178(6): 653 - 654. [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Melamed, E. D. Michos, W. Post, and B. Astor 25-Hydroxyvitamin D Levels and the Risk of Mortality in the General Population Arch Intern Med, August 11, 2008; 168(15): 1629 - 1637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Rizzo, A. M. Abbatecola, M. Barbieri, M. T. Vietri, M. Cioffi, R. Grella, A. Molinari, R. Forsey, J. Powell, and G. Paolisso Evidence for Anti-Inflammatory Effects of Combined Administration of Vitamin E and C in Older Persons with Impaired Fasting Glucose: Impact on Insulin Action J. Am. Coll. Nutr., August 1, 2008; 27(4): 505 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ishigaki, H. Katagiri, J. Gao, T. Yamada, J. Imai, K. Uno, Y. Hasegawa, K. Kaneko, T. Ogihara, H. Ishihara, et al. Impact of Plasma Oxidized Low-Density Lipoprotein Removal on Atherosclerosis Circulation, July 1, 2008; 118(1): 75 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Jager, W. F. Mieler, and J. W. Miller Age-Related Macular Degeneration N. Engl. J. Med., June 12, 2008; 358(24): 2606 - 2617. [Full Text] [PDF]
|
|
|
|
|
|
N. R. Cook, C. M. Albert, J. E. Manson, and for the WACS Investigator Group Clinical Trials of Antioxidant Supplementation in the Prevention of Cardiovascular Events--Reply Arch Intern Med, April 14, 2008; 168(7): 773 - 774. [Full Text]
|
|
|
|
|
|
F. Leenhardt, A. Fardet, B. Lyan, E. Gueux, E. Rock, A. Mazur, E. Chanliaud, C. Demigne, and C. Remesy Wheat Germ Supplementation of a Low Vitamin E Diet in Rats Affords Effective Antioxidant Protection in Tissues J. Am. Coll. Nutr., April 1, 2008; 27(2): 222 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M Ellis, H. K. Tan, R. E Gilbert, D. P R Muller, W. Henley, R. Moy, R. Pumphrey, C. Ani, S. Davies, V. Edwards, et al. Supplementation with antioxidants and folinic acid for children with Down's syndrome: randomised controlled trial BMJ, March 15, 2008; 336(7644): 594 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Slatore, A. J. Littman, D. H. Au, J. A. Satia, and E. White Long-Term Use of Supplemental Multivitamins, Vitamin C, Vitamin E, and Folate Does Not Reduce the Risk of Lung Cancer Am. J. Respir. Crit. Care Med., March 1, 2008; 177(5): 524 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Patterson MD, J. W. Feightner MD MSc, A. Garcia MD PhD, G.-Y. R. Hsiung MD MHSc, C. MacKnight MD MSc, and A. D. Sadovnick PhD Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease Can. Med. Assoc. J., February 26, 2008; 178(5): 548 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Cave, R. T. Hurt, T. H. Frazier, P. J. Matheson, R. N. Garrison, C. J. McClain, and S. A. McClave Obesity, Inflammation, and the Potential Application of Pharmaconutrition Nutr Clin Pract, February 1, 2008; 23(1): 16 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Milman, S. Blum, C. Shapira, D. Aronson, R. Miller-Lotan, Y. Anbinder, J. Alshiek, L. Bennett, M. Kostenko, M. Landau, et al. Vitamin E Supplementation Reduces Cardiovascular Events in a Subgroup of Middle-Aged Individuals With Both Type 2 Diabetes Mellitus and the Haptoglobin 2-2 Genotype: A Prospective Double-Blinded Clinical Trial Arterioscler. Thromb. Vasc. Biol., February 1, 2008; 28(2): 341 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Quiroz, A. Ferrebuz, F. Romero, N. D. Vaziri, and B. Rodriguez-Iturbe Melatonin ameliorates oxidative stress, inflammation, proteinuria, and progression of renal damage in rats with renal mass reduction Am J Physiol Renal Physiol, February 1, 2008; 294(2): F336 - F344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Sheridan and M. A. Beck The Immune Response to Herpes Simplex Virus Encephalitis in Mice Is Modulated by Dietary Vitamin E J. Nutr., January 1, 2008; 138(1): 130 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bardia, I. M. Tleyjeh, J. R. Cerhan, A. K. Sood, P. J. Limburg, P. J. Erwin, and V. M. Montori Efficacy of Antioxidant Supplementation in Reducing Primary Cancer Incidence and Mortality: Systematic Review and Meta-analysis Mayo Clin. Proc., January 1, 2008; 83(1): 23 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tatsioni, N. G. Bonitsis, and J. P. A. Ioannidis Persistence of Contradicted Claims in the Literature JAMA, December 5, 2007; 298(21): 2517 - 2526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Siekmeier, C. Steffen, and W. Marz Role of Oxidants and Antioxidants in Atherosclerosis: Results of In Vitro and In Vivo Investigations Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2007; 12(4): 265 - 282. [Abstract] [PDF]
|
|
|
|
|
|
S. Devaraj, R. Tang, B. Adams-Huet, A. Harris, T. Seenivasan, J. A de Lemos, and I. Jialal Effect of high-dose {alpha}-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1392 - 1398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Syed, N. Khan, F. Afaq, and H. Mukhtar Chemoprevention of Prostate Cancer through Dietary Agents: Progress and Promise Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2193 - 2203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Damian Genetic Associations With Age-Related Macular Degeneration JAMA, October 10, 2007; 298(14): 1637 - 1637. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Cotter, J. Thomas, P. Cassidy, K. Robinette, N. Jenkins, S. R. Florell, S. Leachman, W. E. Samlowski, and D. Grossman N-Acetylcysteine Protects Melanocytes against Oxidative Stress/Damage and Delays Onset of Ultraviolet-Induced Melanoma in Mice Clin. Cancer Res., October 1, 2007; 13(19): 5952 - 5958. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Talegawkar, E. J. Johnson, T. Carithers, H. A. Taylor Jr., M. L. Bogle, and K. L. Tucker Total {alpha}-Tocopherol Intakes Are Associated with Serum {alpha}-Tocopherol Concentrations in African American Adults J. Nutr., October 1, 2007; 137(10): 2297 - 2303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bleys, A. Navas-Acien, and E. Guallar Selenium and Diabetes: More Bad News for Supplements Ann Intern Med, August 21, 2007; 147(4): 271 - 272. [Full Text] [PDF]
|
|
|
|
|
|
N. R. Cook, C. M. Albert, J. M. Gaziano, E. Zaharris, J. MacFadyen, E. Danielson, J. E. Buring, and J. E. Manson A Randomized Factorial Trial of Vitamins C and E and Beta Carotene in the Secondary Prevention of Cardiovascular Events in Women: Results From the Women's Antioxidant Cardiovascular Study Arch Intern Med, August 13, 2007; 167(15): 1610 - 1618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Swanson and R. M. Carnahan Dementia and Comorbidities: An Overview of Diagnosis and Management Journal of Pharmacy Practice, August 1, 2007; 20(4): 296 - 317. [Abstract] [PDF]
|
|
|
|
|
|
H. Hemila and E. R Miller III Evidence-based medicine and vitamin E supplementation Am. J. Clinical Nutrition, July 1, 2007; 86(1): 261 - 262. [Full Text] [PDF]
|
|
|
|
|
|
M. E Wright, K. A Lawson, S. J Weinstein, and D. Albanes Reply to H Hemila and ER Miller III Am. J. Clinical Nutrition, July 1, 2007; 86(1): 262 - 263. [Full Text] [PDF]
|
|
|
|
|
|
M. G Traber Reply to H Hemila and ER Miller III Am. J. Clinical Nutrition, July 1, 2007; 86(1): 263 - 264. [Full Text] [PDF]
|
|
|
|
|
|
A. Agudo, L. Cabrera, P. Amiano, E. Ardanaz, A. Barricarte, T. Berenguer, M. D Chirlaque, M. Dorronsoro, P. Jakszyn, N. Larranaga, et al. Fruit and vegetable intakes, dietary antioxidant nutrients, and total mortality in Spanish adults: findings from the Spanish cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Spain) Am. J. Clinical Nutrition, June 1, 2007; 85(6): 1634 - 1642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Bjelakovic and C. Gluud Surviving Antioxidant Supplements J Natl Cancer Inst, May 16, 2007; 99(10): 742 - 743. [Full Text] [PDF]
|
|
|
|
|
|
Y.-L. Tain, G. Freshour, A. Dikalova, K. Griendling, and C. Baylis Vitamin E reduces glomerulosclerosis, restores renal neuronal NOS, and suppresses oxidative stress in the 5/6 nephrectomized rat Am J Physiol Renal Physiol, May 1, 2007; 292(5): F1404 - F1410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Heyland, R. Dhaliwalm, A. Day, J. Drover, H. Cote, and P. Wischmeyer Optimizing the Dose of Glutamine Dipeptides and Antioxidants in Critically Ill Patients: A Phase I Dose-Finding Study JPEN J Parenter Enteral Nutr, March 1, 2007; 31(2): 109 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. G. Tolman, V. Fonseca, A. Dalpiaz, and M. H. Tan Spectrum of Liver Disease in Type 2 Diabetes and Management of Patients With Diabetes and Liver Disease Diabetes Care, March 1, 2007; 30(3): 734 - 743. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Jiang, I. Kurnikov, N. A. Belikova, J. Xiao, Q. Zhao, A. A. Amoscato, R. Braslau, A. Studer, M. P. Fink, J. S. Greenberger, et al. Structural Requirements for Optimized Delivery, Inhibition of Oxidative Stress, and Antiapoptotic Activity of Targeted Nitroxides J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1050 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Bjelakovic, D. Nikolova, L. L. Gluud, R. G. Simonetti, and C. Gluud Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary Prevention: Systematic Review and Meta-analysis JAMA, February 28, 2007; 297(8): 842 - 857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Michaud, J. P. Karpinski, K. L. Jones, and J. Espirito Dietary supplements in patients with cancer: Risks and key concepts, part 1 Am. J. Health Syst. Pharm., February 15, 2007; 64(4): 369 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Mejia-Rodriguez, D. Sotres-Alvarez, L. M. Neufeld, A. Garcia-Guerra, and C. Hotz Use of Nutritional Supplements among Mexican Women and the Estimated Impact on Dietary Intakes below the EAR and above the UL J. Am. Coll. Nutr., February 1, 2007; 26(1): 16 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Halliwell Dietary polyphenols: Good, bad, or indifferent for your health? Cardiovasc Res, January 15, 2007; 73(2): 341 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The NINDS NET-PD Investigators A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease Neurology, January 2, 2007; 68(1): 20 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M Seddon Multivitamin-multimineral supplements and eye disease: age-related macular degeneration and cataract Am. J. Clinical Nutrition, January 1, 2007; 85(1): 304S - 307S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Dzau, E. M. Antman, H. R. Black, D. L. Hayes, J. E. Manson, J. Plutzky, J. J. Popma, and W. Stevenson The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through Stable Coronary Artery Disease) Circulation, December 19, 2006; 114(25): 2850 - 2870. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Espeland and V. W. Henderson Preventing Cognitive Decline in Usual Aging Arch Intern Med, December 11, 2006; 166(22): 2433 - 2434. [Full Text] [PDF]
|
|
|
|
|
|
J. Frank, A. Budek, T. Lundh, R. S. Parker, J. E. Swanson, C. F. Lourenco, B. Gago, J. Laranjinha, B. Vessby, and A. Kamal-Eldin Dietary flavonoids with a catechol structure increase {alpha}-tocopherol in rats and protect the vitamin from oxidation in vitro J. Lipid Res., December 1, 2006; 47(12): 2718 - 2725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Roberson and L. Mucke 100 Years and Counting: Prospects for Defeating Alzheimer's Disease Science, November 3, 2006; 314(5800): 781 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E Wright, K. A Lawson, S. J Weinstein, P. Pietinen, P. R Taylor, J. Virtamo, and D. Albanes Higher baseline serum concentrations of vitamin E are associated with lower total and cause-specific mortality in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Am. J. Clinical Nutrition, November 1, 2006; 84(5): 1200 - 1207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-P. Ng, P.-C. Chiam, T. Lee, H.-C. Chua, L. Lim, and E.-H. Kua Curry Consumption and Cognitive Function in the Elderly Am. J. Epidemiol., November 1, 2006; 164(9): 898 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B McCormick The dubious use of vitamin-mineral supplements in relation to cardiovascular disease. Am. J. Clinical Nutrition, October 1, 2006; 84(4): 680 - 681. [Full Text] [PDF]
|
|
|
|
|
|
J. Bleys, E. R Miller III, R. Pastor-Barriuso, L. J Appel, and E. Guallar Vitamin-mineral supplementation and the progression of atherosclerosis: a meta-analysis of randomized controlled trials. Am. J. Clinical Nutrition, October 1, 2006; 84(4): 880 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang, M. H Gail, Y.-q. Wang, L. M. Brown, K.-f. Pan, J.-l. Ma, H. Amagase, W.-c. You, and R. Moslehi A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. Am. J. Clinical Nutrition, October 1, 2006; 84(4): 912 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Berger Antioxidant Micronutrients in Major Trauma and Burns: Evidence and Practice Nutr Clin Pract, October 1, 2006; 21(5): 438 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Lichtenstein, L. J. Appel, M. Brands, M. Carnethon, S. Daniels, H. A. Franch, B. Franklin, P. Kris-Etherton, W. S. Harris, B. Howard, et al. Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006 Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2186 - 2191. [Full Text] [PDF]
|
|
|
|
|
|
S. Liu, I-M. Lee, Y. Song, M. Van Denburgh, N. R. Cook, J. E. Manson, and J. E. Buring Vitamin E and Risk of Type 2 Diabetes in the Women's Health Study Randomized Controlled Trial. Diabetes, October 1, 2006; 55(10): 2856 - 2862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Mares Potential value of antioxidant-rich foods in slowing age-related macular degeneration. Arch Ophthalmol, September 1, 2006; 124(9): 1339 - 1340. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fisher, K. Lees, and J. D. Spence Nutrition and Stroke Prevention Stroke, September 1, 2006; 37(9): 2430 - 2435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Shenkin Micronutrients in health and disease. Postgrad. Med. J., September 1, 2006; 82(971): 559 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Czernichow, A. Couthouis, S. Bertrais, A.-C. Vergnaud, L. Dauchet, P. Galan, and S. Hercberg Antioxidant supplementation does not affect fasting plasma glucose in the Supplementation with Antioxidant Vitamins and Minerals (SU.VI.MAX) study in France: association with dietary intake and plasma concentrations. Am. J. Clinical Nutrition, August 1, 2006; 84(2): 395 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hemila, J. Virtamo, D. Albanes, and J. Kaprio The effect of vitamin e on common cold incidence is modified by age, smoking and residential neighborhood. J. Am. Coll. Nutr., August 1, 2006; 25(4): 332 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Davies, G. Davey Smith, R. Harbord, G. E. Bekkering, J. A. C. Sterne, R. Beynon, and S. Thomas Nutritional interventions and outcome in patients with cancer or preinvasive lesions: systematic review. J Natl Cancer Inst, July 19, 2006; 98(14): 961 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Knight and S. D. Fihn Update in General Internal Medicine Ann Intern Med, July 4, 2006; 145(1): 52 - 61. [Full Text] [PDF]
|
|
|
|
|
|
A. H. Lichtenstein, L. J. Appel, M. Brands, M. Carnethon, S. Daniels, H. A. Franch, B. Franklin, P. Kris-Etherton, W. S. Harris, B. Howard, et al. Diet and Lifestyle Recommendations Revision 2006: A Scientific Statement From the American Heart Association Nutrition Committee Circulation, July 4, 2006; 114(1): 82 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. Clarke, A. J. Hooper, H. A. Headlam, J. H.Y. Wu, K. D. Croft, and J. R. Burnett Assessment of Tocopherol Metabolism and Oxidative Stress in Familial Hypobetalipoproteinemia Clin. Chem., July 1, 2006; 52(7): 1339 - 1345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Hanje, B. Fortune, M. Song, D. Hill, and C. McClain The Use of Selected Nutrition Supplements and Complementary and Alternative Medicine in Liver Disease Nutr Clin Pract, June 1, 2006; 21(3): 255 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Arroyo A 76-year-old man with macular degeneration. JAMA, May 24, 2006; 295(20): 2394 - 2406. [Full Text] [PDF]
|
|
Read all Rapid Responses
